NetNoggin® releases results from “Levels of Caregiving for Patients with Alzheimer’s Disease” research study

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

FREDERICK, Md., July 17, 2019 /PRNewswire/ — NetNoggin® released detailed results from a netnographic-qualitative research study, which investigated levels of caregiving for patients with Alzheimer’s disease and was presented at the Alzheimer’s Association International Conference® (AAIC) 2019, held in Los Angeles, California, July 14 – 18. NetNoggin® conducted a comparative analysis between secondary literature and primary netnographic data to determine common threads and gaps regarding different caregiving classifications. Results from this research demonstrate that a new classification of caregiving is needed and should be used as an educational resource to prepare new caregivers for their journey.

Inspired by the consumer. (PRNewsfoto/NetNoggin)Inspired by the consumer. (PRNewsfoto/NetNoggin)

“Our research shows caregivers desire pathways or ‘levels’ to monitor their own journey, while tracking their patients’ progression,” said Diana Conger, CEO of NetNoggin®. “Our research is a starting point to show caregivers what their path may look like, how their journey may change, and offer interventions/support at the right time and place.”

Visit https://netnoggin.net/news to request a PDF of the research, “Levels of Caregiving for Patients with Alzheimer’s Disease.”

NetNoggin® continues to participate in the Alzheimer’s disease space with their syndicated report, NetNog: #genesis® Alzheimer’s Disease (including MCI). This report captures insights from a large volume of rich contextual conversations, with raw and unbiased lexicon, occurring online. Patients and caregivers write in the present, and there is no bias related to recall, unlike traditional research (interviews or surveys). For more information on NetNog: #genesis® Alzheimer’s Disease (including MCI), visit https://netnoggin.net/disease-focused-research.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops. NetNoggin® was established in 2011. The founder, Diana Conger, has been involved in bringing over 20 pharmaceutical products to market and has in-depth knowledge of over 50 disease-states.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-results-from-levels-of-caregiving-for-patients-with-alzheimers-disease-research-study-300885928.html

SOURCE NetNoggin

Staff

Recent Posts

TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…

15 hours ago

Introducing Tempus One in the EHR with Integrated Guidelines

The AI-enabled clinical assistant is available to query patient data across the EHR as well…

18 hours ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…

18 hours ago

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep,…

18 hours ago